Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03184571 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer Metastatic
NSCLC Stage IV
Adenocarcinoma of Lung

Interventions

DRUG: Pembrolizumab
DRUG: Bemcentinib

Sponsor

BerGenBio ASA

Collaborators

[object Object]